Immuneering Corporation
IMRX
$3.95
-$0.09-2.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.27% | -0.32% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.51% | -10.58% | |||
| Operating Income | -11.51% | 10.58% | |||
| Income Before Tax | -16.24% | 22.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.24% | 22.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.24% | 22.62% | |||
| EBIT | -11.51% | 10.58% | |||
| EBITDA | -11.54% | 10.62% | |||
| EPS Basic | -16.12% | 52.47% | |||
| Normalized Basic EPS | -17.96% | 51.82% | |||
| EPS Diluted | -16.12% | 52.47% | |||
| Normalized Diluted EPS | -17.96% | 51.82% | |||
| Average Basic Shares Outstanding | 0.11% | 62.82% | |||
| Average Diluted Shares Outstanding | 0.11% | 62.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||